1334921-03-7

Basic information

• Product Name: TAI-1
• Synonyms: N-(4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide
• CAS NO: 1334921-03-7
• Molecular Formula: C₂₄H₂₁N₃O₃S
• Molecular Weight: 431.50684
• Product Categories: Inhibitors
• Mol File: 1334921-03-7.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.281±0.06 g/cm3(Predicted)
• Solubility: ≥43.2 mg/mL in DMSO; insoluble in H2O; ≥3.17 mg/mL in EtOH
• PKA: 5.38±0.70(Predicted)
• CAS DataBase Reference: TAI-1(CAS DataBase Reference)
• NIST Chemistry Reference: TAI-1(1334921-03-7)
• EPA Substance Registry System: TAI-1(1334921-03-7)

Safety Data

• Hazardous Substances Data: 1334921-03-7(Hazardous Substances Data)

Usage

General Description

TAI-1 is a small molecule chemical compound that has shown promise as a potential cancer treatment. It inhibits the activity of protein tyrosine phosphatase 1B (PTP1B), a key enzyme involved in regulating cell signaling pathways and controlling cell growth and survival. TAI-1 has been found to induce apoptosis, or programmed cell death, in various cancer cell lines both in vitro and in vivo. It has also been shown to inhibit the growth and proliferation of cancer cells, suggesting its potential as a targeted therapy for cancer treatment. Additionally, TAI-1 has demonstrated synergistic effects with other anti-cancer agents, making it a potentially valuable component in combination therapies for cancer. Further research and clinical trials are needed to fully understand the therapeutic potential of TAI-1 in the treatment of cancer.

Upstream product

• 1334922-22-3 2-bromo-1-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone 
• 83759-88-0 1-(4-amino-2,6 dimethylphenyl)ethanone 
• 35887-71-9 1-(4-chloro-2,6-dimethylphenyl)ethanone 
• 14254-57-0 4-(chlorocarbonyl)pyridine 
• 1334922-24-5 4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)thiazol-2-amine 
• 1334922-19-8 1-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone 

Relevant articles and documents

Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: Optimization of in vitro potencies and pharmacokinetic properties

A series of 4-aryl-N-arylcarbonyl-2-aminothiazoles of scaffold 4 was designed and synthesized as Hec1/Nek2 inhibitors. Structural optimization of 4 led to compound 32 bearing C-4′ 4-methoxyphenoxy and 4-(o-fluoropyridyl) carbonyl groups that showed low nanomolar in vitro antiproliferative activity (IC50: 16.3-42.7 nM), high intravenous AUC (64.9 μM·h, 2.0 mg/kg) in SD rats, and significant in vivo antitumor activity (T/C = 32%, 20 mg/kg, IV) in mice bearing human MDA-MB-231 xenografts. Cell responses resulting from Hec1/Nek2 inhibition were observed in cells treated with 32, including a reduced level of Hec1 coimmunoprecipitated with Nek2, degradation of Nek2, mitotic abnormalities, and apoptosis. Compound 32 showed selectivity toward cancer cells over normal phenotype cells and was inactive in a [ 3H]astemizole competitive binding assay for hERG liability screening. Therefore, 32 is as a good lead toward the discovery of a preclinical candidate targeting Hec1/Nek2 interaction.